Operator-led venture capital investing in Signal-Rich NeuroTech and High Impact Medtech.
Breakout Ventures eyes neuroscience and AI with new fund
The venture capital firm has $114 million to invest
NeuroNYC
As the global leader in finance, policy, art, research, and medicine, the region is well-positioned to lead neurotech. We help foster and promote the local neurotech ecosystem: clinics, companies, funders, labs, and users.
Highline Beta | Corporate Venture Studios & Venture Building
We build ventures and venture studios with corporate partners and family offices through rigorous process, entrepreneurial grit, and capital.
NYC Neurotech Company List
HOME | A-Force Ventures
A-Force Ventures is an early-stage venture capital fund that invests in female-led consumer, internet, and mobile startups.
Partner with Neuroscience
Partner with J&J Neuroscience to collaborate on licensing, academia, venture deals and shared innovation across Alzheimer’s, Parkinson’s and more.
Tagus Capital — DeepTech Venture Capital | Oxford
Tagus Capital is a DeepTech venture capital fund based in Oxford
Why A Neurotech VC Bet On Anthropic: Intelligence, Interpretability, and the NeuroAI Stack — Kaleida Capital
Why would a neurotech VC bet on Anthropic? This article examines how frontier AI, neuroscience, model behavior, and intelligent systems intersect within Kaleida Capital’s NeuroAI thesis and the infrastructure shaping next-generation intelligence.
Former Meta AR Neural Band Leader Targets $2.5 Billion Valuation for Brain-Inspired Power-Sipping AI
Thomas Reardon, the former Meta executive who built the Neural Band wristband, is raising capital for a new startup called Flourish at a target valuation of $2.
Just back from a truly impactful few days at Asilomar for the Brain and Mind, hosted by the brilliant team at BrainMind. The spirit of the 1975 Recombinant DNA Conference felt palpable as we gathered… | Sean White
Just back from a truly impactful few days at Asilomar for the Brain and Mind, hosted by the brilliant team at BrainMind. The spirit of the 1975 Recombinant DNA Conference felt palpable as we gathered to chart ethical standards for the accelerating field of Neurotech. While our focus was on neuroethics, from investor diligence questions and board-level risk matrices to user/stakeholder engagement and toolkits for neuroentrepreneurs, the key themes shared a powerful parallel with AI Ethics: maintain and enhance human agency, combat misuse and mistrust, and acknowledge that innovation is moving faster than its guardrails. Both fields present novel challenges that demand we adapt our existing frameworks and principles to meet new challenges. At the heart of it all is human agency. Whether we're discussing neurodevices or large language models, our core responsibility as builders, executives, investors, and policymakers is to ensure people are informed, in control, and never burdened to fight for their own empowerment or autonomy. We have the fundamental responsibility to care about the people we serve. This commitment to responsible, human-centric development is fundamental to our work at Inflection AI. We're building with emotional intelligence at the core. Every product decision we make starts with a simple question: does this expand what people can do, or does it quietly shift the burden onto them? AI should work for the humans using it, amplifying judgment, not replacing it. Earning trust through transparency rather than demanding it through dependency. A special thank you to Diana Saville for once again outdoing herself at every event and to Michael McCullough, MD for his endless support of the ecosystem. And to all the Braingels who showed up and rolled up their sleeves! Let's translate the urgency from Asilomar into action and continue to drive positive change.
Philanthropy 2.0: What the Evolution of For-Profit Investment Tells Us About the Future of Giving
Gaps in philanthropic funding for era-defining science and discovery demand a new approach. In this piece, we look at how learning from venture capital is a game changer for catalytic philanthropy.
Philanthropy 2.0: What the Evolution of For-Profit Investment Tells Us About the Future of Giving
Gaps in philanthropic funding for era-defining science and discovery demand a new approach. In this piece, we look at how learning from venture capital is a game changer for catalytic philanthropy.
Massively Scalable Neurotechnologies
Backed by £50m, this programme sits within the Scalable Neural Interfaces opportunity space and is seeking radically new ways to deliver responsive neurotechnologies to the brain without brain surgery.
QuSpin Technology Takes Brain Scanning to the Next Level | Seed
NIH's SEED Fund: Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs Plus entrepreneurial and product development support for academic and small business innovators
Jeff Bezos Is Funding a Wild Hunt for the Brain’s ‘Core Algorithm’
With $500 million in funding and a reported $2.5 billion valuation, Flourish wants to reinvent AI by putting real neurons under the microscope.
